Type 2 diabetes
Conditions
Interventions
Insulin + Pioglitazone (pioglitazone was started with 15mg/day and titrated up to 30mg/day)
Insulin + Metformin (metformin was started with 500mg/day and titrated up to 2250mg/day)
Sponsors
Chigasaki Municipal Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) A consent form for participating in this study is submitted 2) Patients with type 2 diabetes 3) Patients treated with insulin therapy 4) HbA1c >= 7.5% 5) BMI<35kg/m2
Exclusion criteria
Exclusion criteria: 1) Patients with type 1 diabetes 2) Patients receiving thiazolidiones or biguanides 3) Heart failure defined as NYHA class III or above 4) Having allergy to thiazolidiones or biguanides 5) Patients with severe liver failure or renal failure 6) History of acute coronary syndrome or cerebrovascular accident with in 3 months 7) Pregnant or breastfeeding 8) Patients with familial hypercholesterolemia 9) Other patients determined to be inappropriate by physician
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes of HbA1c from the baseline to 24 weeks later | — |
Secondary
| Measure | Time frame |
|---|---|
| body weight change, fasting plasma glucose, postprandial plasma glucose, insulin dose requirements, lipid profile(Total cholesterol,Triglyceride,LDL-cholesterol,HDL-cholesterol), albuminuria, Cystatin C, High sensitivity CRP | — |
Countries
Japan
Contacts
Public ContactYoshinobu Kondo
Chigasaki Municipal Hospital Department of Endocrinology and Metabolism
Outcome results
None listed